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Aim: To share the Tuscany single-centre experience about the employing of the novel
therapeutic radiopharmaceutical 223Ra in the treatment planning of mCRPC pts.
Methods: Thirteen pts were treated from August 2013 to date. Five pts have been
enrolled in the Bayer EAP and 8 have been treated as routine application. Pts (age
67 ± 8.4 yrs, median PSA 149.5 ng/mL, excluding one case of neuroendocrine
differentiation) received 223Ra 50 kBq/kg i.v. on day 1 every 28 days for a maximum of
6 cycles. Pre-treatment evaluations were made using bone scan, and WB-CT in order
to exclude visceral metastases. Pts have been evaluated at every cycle with complete
blood chemistry (including serum ALP, PSA and LDH), pain VAS score, quality of life
questionnaire (FACT-p), and analgesic consumption. The last group of pts started the
cure in March 2015.
Results: At the current time-point 13 patients received 72 cycles of 223Ra. No issues in
vial manipulation, dose preparation and administration occurred. A multidisciplinary
team has followed pts during both screening and treatment period. Only 3 cycles have
been delayed (2 due to blood toxicity, 1 due to drug’s manufacturing hitches) and 3 pts
discontinued the treatment (2 because of non reversible blood toxicity and anorexia,
and 1 because of hepatic disease progression). Regarding valuable clinical data, bone
marrow toxicity resulted in G3 anemia in 2 pts, G2 neutropenia in 2 pts, and G1
thrombocytopenia in 1 patient. Anorexia G3 occurred in 3 pts, while no case of
diarrhoea was observed. Biomarkers response showed median ALP decline of -50% and
median LDH decline of -5%. We observed mean PSA decline of -15%. One patient who
presented with superscan at baseline received 223Ra 5 cycles before hepatic
progression, showing ALP levels decline of -89%, LDH -44% and PSA -48%. According
to VAS score and FACT-p, most of pts had bone pain relief and reduced pain drugs
intake.
Conclusion: Single-centre experience shows the feasibility and efficacy of therapy with
223Ra in mCRPC pts. Multidisciplinary careful evaluation of bone marrow toxicity and
gastrointestinal adverse events must be carried out to optimize individual compliance.
Palliative effect allows decreasing pain drugs consume. The mild toxicity could permit
the use of 223Ra in combination with other treatments.
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